BETAINE Drug Patent Profile

Which patents cover Betaine, and when can generic versions of Betaine launch?

Betaine is a drug marketed by Eton and Novitium Pharma and is included in two NDAs.

The generic ingredient in BETAINE is betaine. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the betaine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Betaine

A generic version of BETAINE was approved as betaine by NOVITIUM PHARMA on November 23^rd, 2021.

Summary for BETAINE

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	97
Clinical Trials:	28
Patent Applications:	3,435
DailyMed Link:	BETAINE at DailyMed

Recent Clinical Trials for BETAINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Southern California Institute for Research and Education	PHASE2
University of Nevada, Las Vegas	PHASE4
Xuanwu Hospital, Beijing	PHASE2

See all BETAINE clinical trials

Pharmacology for BETAINE

Drug Class	Methylating Agent
Mechanism of Action	Methylating Activity

Anatomical Therapeutic Chemical (ATC) Classes for BETAINE

A16AA	Amino acids and derivatives
A16A	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for BETAINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eton	BETAINE	betaine	FOR SOLUTION;ORAL	210508-001	Jan 28, 2022	AB	RX	No	No
Novitium Pharma	BETAINE	betaine	FOR SOLUTION;ORAL	214864-001	Nov 23, 2021	AB	RX	No	No

Betaine Drug Market Dynamics, Cystadane Revenue Outlook, and Patent Exclusivity

Last updated: September 4, 2026

Betaine is a mature orphan drug used primarily as betaine anhydrous for homocystinuria. The leading U.S. branded product is Cystadane, marketed by Recordati Rare Diseases. Its commercial profile is defined by a small diagnosed population, chronic treatment, orphan-disease pricing, limited therapeutic substitution, and low transparency because Recordati does not report Cystadane revenue separately. The core FDA exclusivity period expired years ago, while current market protection depends more on regulatory know-how, supply reliability, physician familiarity, reimbursement, and formulation execution than on visible composition-of-matter patents.

What is betaine used to treat?

Betaine anhydrous lowers plasma homocysteine by remethylating homocysteine to methionine. FDA-approved use covers homocystinuria caused by deficiencies or defects involving:

• Cystathionine beta-synthase, or CBS
• 5,10-methylenetetrahydrofolate reductase, or MTHFR
• Cobalamin metabolism, including cblC, cblD, cblE and related disorders

Cystadane is administered orally as a powder that is mixed with food, liquid or formula. Treatment is usually chronic and may be combined with pyridoxine, folate, vitamin B12, dietary methionine restriction, and nutritional support. The FDA label recommends plasma homocysteine monitoring and dose adjustment according to biochemical response. [1]

How large is the betaine-treated patient population?

Homocystinuria is rare. CBS deficiency has been estimated at approximately one case per 200,000 to 335,000 births in many populations, although prevalence is materially higher in selected countries and founder populations. MTHFR and intracellular cobalamin disorders have different epidemiology and are frequently identified through newborn screening or genetic testing. [2]

The commercial addressable population is smaller than the theoretical prevalence because:

1. Some patients remain undiagnosed.
2. Some patients die or sustain irreversible complications before diagnosis.
3. Treatment may be initiated with off-label or compounded betaine rather than Cystadane.
4. Patients may receive imported products outside the United States.
5. Pediatric and adult diagnosis rates differ by country.

The market therefore has low volume but high treatment persistence among diagnosed patients.

What is the FDA regulatory status of Cystadane?

Cystadane is FDA-approved betaine anhydrous for homocystinuria. The product received orphan-drug approval in the United States in 1996. [3] Recordati Rare Diseases is the current U.S. commercial entity identified in the product labeling.

Regulatory attribute	Cystadane status
Active ingredient	Betaine anhydrous
Chemical identity	Trimethylglycine; CAS No. 107-43-7
Dosage form	Oral powder
U.S. indication	Homocystinuria
FDA approval	1996
Regulatory pathway	Orphan drug approval
U.S. marketing company	Recordati Rare Diseases
Biosimilar pathway	Not applicable
Typical treatment pattern	Chronic, often lifelong
Prescription status	Prescription drug

Cystadane is a small-molecule chemical product, not a biologic. A follow-on entrant would generally pursue an abbreviated new drug application, or ANDA, if it could demonstrate pharmaceutical equivalence and bioequivalence. The product’s orphan indication does not create a biosimilar market.

What patents protect betaine and Cystadane?

The active ingredient betaine is an old, naturally occurring compound. Its basic chemical identity is not a credible source of current U.S. composition-of-matter exclusivity. The commercial protection question is therefore narrower: whether Cystadane or competing betaine products have active patents covering formulation, manufacturing, dosage, or method of use.

The publicly visible U.S. protection profile is limited:

Protection category	Commercial assessment
Basic betaine molecule	Effectively off-patent
FDA orphan exclusivity	Expired
New chemical entity exclusivity	Not applicable to the current product
Formulation patents	No widely recognized blocking U.S. patent estate identified for the marketed powder
Method-of-use patents	Potentially relevant in individual jurisdictions, but not the primary U.S. barrier
Manufacturing patents	Could protect process economics or purity, but would not necessarily block all ANDA entry
Orange Book patent listing	No material blocking patent estate is publicly associated with Cystadane in standard Orange Book searches
Trade secrets	Potentially relevant to sourcing, quality control and manufacturing consistency

The absence of a visible Orange Book patent does not eliminate litigation risk. A sponsor can assert patents outside the Orange Book, including process, formulation, or use patents. Such patents may support infringement claims but generally do not create the same automatic FDA approval delay as a properly listed Orange Book patent challenged under Paragraph IV.

When did betaine lose exclusivity?

Cystadane’s seven-year orphan-drug exclusivity period would have expired approximately in 2003, assuming the 1996 approval date. Orphan exclusivity prevents FDA approval of the same drug for the same indication during the protected period, subject to statutory exceptions. It does not prevent all competing betaine products in every indication or jurisdiction. [4]

The exclusivity timeline is therefore:

Event	Approximate timing
U.S. orphan approval	1996
Seven-year orphan exclusivity expiry	2003
Current status	No active original orphan exclusivity
Current protection basis	Brand recognition, supply, reimbursement, clinical practice and possible product-specific IP

Betaine is not protected by pediatric exclusivity or new chemical entity exclusivity associated with the current marketed product. Any patent term must be assessed patent by patent. No core patent expiration date is commercially determinative because the molecule itself is old and the visible Cystadane estate is not centered on a long-lived composition patent.

What is the Orange Book status of Cystadane?

The FDA Orange Book records approved drug products and identifies certain patent and exclusivity information relevant to generic approval. Cystadane’s commercial risk is not driven by a prominent Orange Book-listed patent blocking an ANDA. [5]

This creates a structurally different competitive profile from high-value branded drugs that rely on multiple listed formulation and method-of-use patents. For Cystadane, a generic sponsor would likely focus on:

• Pharmaceutical equivalence to betaine anhydrous
• Powder particle characteristics
• Stability and moisture control
• Packaging and dosing instructions
• Assay and impurity specifications
• Bioequivalence strategy
• Labeling differences tied to the approved indication

Because betaine is administered for a biochemical endpoint rather than a conventional systemic exposure target, a generic sponsor may face technical questions regarding the appropriate bioequivalence approach. The active ingredient’s established use could support regulatory development, but the product’s orphan-disease population could make clinical or pharmacokinetic studies operationally difficult.

Are there Paragraph IV challenges to Cystadane?

No high-profile, publicly established Paragraph IV litigation campaign against Cystadane is a defining feature of the current market record. The limited patient population reduces the expected return from a conventional ANDA challenge, while the product’s formulation is relatively straightforward.

A Paragraph IV filing would create several possible commercial outcomes:

1. A first generic entrant could seek rapid market share through lower pricing.
2. A generic could enter after resolving patent disputes without a public trial.
3. Recordati could defend the product through non-patent commercial measures, including contracting, patient-support services and distribution control.
4. A generic sponsor could supply betaine under a different trade name without materially displacing the branded product if physicians and payers value continuity of supply.

The litigation economics are less attractive than for a product with hundreds of millions of dollars in annual sales. A challenger would need to estimate the addressable patient count, expected net price, market share, regulatory cost, and the potential for compounded or imported alternatives to limit branded-product revenue.

What formulations are protected by betaine patents?

Cystadane is a powder formulation. The principal technical vulnerabilities are not complex delivery systems but manufacturing and handling requirements.

Powder formulation and packaging

Betaine is highly water-soluble and hygroscopic. A commercial powder must maintain potency and flow properties during storage. Packaging, moisture protection, container-closure integrity, and reproducible dosing can affect product quality.

A formulation patent could theoretically cover:

• Particle-size distribution
• Moisture-control excipients
• Granulation or agglomeration
• Flavoring or palatability
• Unit-dose packaging
• Reconstitution or mixing instructions
• Stability-enhancing packaging systems

A formulation patent would have to offer a meaningful performance advantage to create durable commercial protection. A generic sponsor may avoid infringement by using different excipients, packaging or manufacturing conditions.

Compounded betaine

Compounding pharmacies and specialty suppliers may provide betaine formulations, but compounded products do not automatically have the same FDA approval status, quality system, labeling, or manufacturing controls as Cystadane. The presence of compounded supply can place a ceiling on pricing, especially for price-sensitive payers and families, but it may not fully replace an FDA-approved product for patients requiring reliable specifications and reimbursement support.

How strong is the betaine patent estate?

The betaine patent estate is weak at the molecule level and appears limited at the marketed-product level. Its practical strength is better described as moderate commercial defensibility rather than strong patent exclusivity.

Factor	Assessment
Molecule patent	Weak or unavailable because betaine is an old compound
Orphan exclusivity	Expired
Orange Book position	No prominent blocking patent identified
Formulation complexity	Low to moderate
Manufacturing barriers	Moderate, primarily quality and moisture control
Patient switching risk	Moderate because treatment is chronic and rare-disease specialists manage care
Generic economics	Uncertain due to small population
Brand commercial moat	Moderate through supply, reimbursement and physician continuity
Long-term legal exclusivity	Limited

The most important barriers are operational. A manufacturer must produce a consistent pharmaceutical-grade material, maintain regulatory compliance, establish specialty distribution, and secure reimbursement for a small number of patients. These barriers can delay entry without providing patent exclusivity.

What is the financial trajectory for betaine and Cystadane?

Recordati reports company-wide financial results but does not generally disclose a standalone Cystadane revenue line in its public financial reporting. As a result, precise product revenue, growth rate, gross margin, and patient count cannot be derived from the company’s consolidated statements. [6]

The financial trajectory can be analyzed through market structure rather than reported product sales.

Revenue drivers

Cystadane revenue is influenced by:

• Number of diagnosed homocystinuria patients
• Treatment duration and dose
• Annual price increases
• Geographic reimbursement
• Patient adherence
• Switching to generic or compounded betaine
• Supply continuity
• Expansion of newborn screening and genetic diagnosis

The patient base is small, but treatment is typically chronic. That produces recurring revenue and lower dependence on new patient starts than an acute-care medicine. Revenue growth is more likely to come from price, diagnosis and geographic expansion than from large volume increases.

Revenue constraints

The product faces structural limits:

• Rare disease prevalence restricts unit growth.
• The active ingredient is inexpensive to synthesize.
• The drug lacks a strong molecule-level patent barrier.
• Generic entry is legally possible.
• Compounding can provide price competition.
• Payers may scrutinize high annual treatment costs for an old chemical entity.
• Patients can often remain on therapy for many years, limiting annual prescription growth.

Financial scenario framework

Scenario	Market outcome	Revenue effect
Base case	Cystadane retains most diagnosed patients; no major generic launch	Stable to modest growth driven by price and diagnosis
Downside case	Approved generic or credible compounded alternative gains access	Net price and brand share decline
Upside case	More newborn screening, improved genetic diagnosis and broader international reimbursement	Patient count and recurring revenue increase
Severe downside case	Multiple suppliers enter and payers mandate substitution	Rapid erosion in branded revenue

The most likely trajectory for a mature orphan product is stable nominal revenue with limited volume growth, followed by step-down risk if a well-funded generic sponsor enters. The timing of that step-down is more important than the underlying growth rate.

Which companies are challenging or competing with Cystadane?

The competitive field is fragmented rather than dominated by a single direct rival.

Direct pharmaceutical competition

Potential competitors include:

• Generic betaine anhydrous suppliers
• Compounding pharmacies
• Regional pharmaceutical companies selling betaine under local brands
• Imported products distributed through rare-disease channels

Public information does not establish a major, sustained U.S. Paragraph IV campaign comparable to challenges involving large primary-care drugs.

Indirect clinical competition

Cystadane also competes with treatment strategies that reduce clinical demand or delay initiation:

• Dietary methionine restriction
• Pyridoxine-responsive therapy in CBS deficiency
• Folate and vitamin B12 treatment
• Newborn screening and early intervention
• Specialist-directed nutritional management

These approaches usually complement rather than replace betaine. Their effect is more likely to influence dose, timing and persistence than eliminate use.

What is the biosimilar risk for betaine?

There is no biosimilar risk in the technical regulatory sense. Biosimilars are biological products evaluated against a reference biologic. Betaine is a chemically synthesized small molecule.

The relevant risk is generic substitution. A generic betaine product could seek approval through the ANDA pathway, subject to FDA requirements for pharmaceutical equivalence and bioequivalence. [7] The commercial impact would depend on whether payers impose substitution, whether specialists trust the entrant, and whether the generic can provide reliable supply for a rare-disease population.

How does betaine compare with other orphan drugs?

Betaine has a weaker legal moat than many modern orphan drugs but may have stronger persistence characteristics than short-course therapies.

Attribute	Betaine/Cystadane	Newer orphan medicines
Active ingredient age	Old chemical entity	Often novel
Molecule patent	Limited	Often strong
Orphan exclusivity	Expired	Frequently active
Patient population	Very small	Small to moderate
Treatment duration	Often lifelong	Variable
Manufacturing complexity	Relatively low	Often high
Generic risk	Meaningful	Often delayed by patents and exclusivity
Revenue visibility	Low at product level	Often disclosed for larger products
Commercial moat	Clinical continuity and supply	Patents, exclusivity, manufacturing and clinical data

Betaine’s risk profile resembles other old orphan drugs whose commercial value depends on chronic use and the absence of an attractive generic business case.

What geographic markets matter for betaine?

The United States is commercially important because of orphan-drug pricing and specialized reimbursement. Europe is also relevant, with Cystadane marketed through Recordati’s rare-disease operations and national reimbursement systems. Market access differs materially by country.

Key geographic variables include:

• Newborn-screening coverage
• Availability of metabolic specialists
• National reimbursement decisions
• Use of imported products
• Local compounding practices
• Registration requirements
• Distribution through hospital pharmacies or specialty pharmacies

In lower-income markets, betaine may be available as a chemical or compounded product without the branded formulation. That expands clinical availability but weakens branded pricing and may create quality-control differences.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are practical rather than patent-based. A supplier must control:

• Identity and purity of betaine anhydrous
• Water content and hygroscopicity
• Particle size and blend uniformity
• Stability through shelf life
• Container-closure performance
• Microbial and elemental impurity controls
• Batch-to-batch consistency
• Global supply and release testing

A process patent covering a specific synthesis or purification route would not necessarily prevent entry using an alternative process. Trade secrets may protect process parameters, supplier qualification, analytical methods and packaging design, but they are difficult to value externally.

Key Takeaways

• Betaine anhydrous is an established orphan drug for homocystinuria, with Cystadane as the leading U.S. branded product.
• FDA approval dates to 1996, and the seven-year orphan exclusivity period expired approximately in 2003.
• The active ingredient is an old chemical entity with no credible current molecule-level exclusivity.
• No prominent Orange Book-listed patent estate is publicly associated with Cystadane.
• Generic substitution, compounding and regional betaine products are the principal competitive risks.
• Recordati does not generally disclose standalone Cystadane revenue, preventing a precise product-level financial model from public company filings.
• Revenue is likely supported by chronic treatment, orphan pricing and patient continuity, while volume growth is constrained by the small diagnosed population.
• The strongest commercial barriers are manufacturing quality, reimbursement, specialty distribution and physician confidence, not patents.
• Biosimilar risk does not apply. The relevant regulatory risk is an ANDA-based generic entrant.
• The most probable financial path is stable to modest nominal growth until a credible generic or payer-driven substitution event changes net pricing.

FAQs

Is betaine an FDA-approved drug?

Yes. Betaine anhydrous is FDA-approved as Cystadane for homocystinuria caused by defects involving homocysteine metabolism.

Is Cystadane still protected by orphan-drug exclusivity?

No. The original seven-year U.S. orphan exclusivity associated with the 1996 approval expired approximately in 2003.

Can a generic manufacturer make betaine?

Yes. Betaine is an old small-molecule active ingredient, and a qualified manufacturer may pursue an ANDA or another applicable regulatory pathway.

Is betaine included in the biosimilar market?

No. Betaine is a small molecule, not a biologic. Competitive products would be generics or alternative formulations, not biosimilars.

Does Recordati disclose Cystadane sales separately?

Public company reporting generally does not provide a standalone Cystadane revenue line. Financial analysis therefore relies on patient, pricing, reimbursement and competitive assumptions rather than reported product-level revenue.

References

1. U.S. Food and Drug Administration. (2023). Cystadane (betaine anhydrous) prescribing information. Recordati Rare Diseases, Inc.

2. Morris, A. A. M., Kožich, V., Santra, S., Andria, G., Ben-Omran, T. I., Chakrapani, A. B., Crushell, E., Henderson, M. J., Hochuli, M., Huemer, M., Janošíková, B., Kırmızıbekmez, H., McNulty, J., Pastore, A., Rocha, J. C., Sakamoto, O., Yap, S., and the international consensus group. (2017). Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. Journal of Inherited Metabolic Disease, 40(1), 49-74.

3. U.S. Food and Drug Administration. (1996). Cystadane approval history and orphan-drug designation records. FDA.

4. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.

5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, 45th edition. FDA.

6. Recordati S.p.A. (2024). Annual report and financial statements. Recordati.

7. U.S. Food and Drug Administration. (2023). ANDA submissions: Content and format. FDA.